Key result
Review examines telmisartan versus losartan in diabetic kidney disease and AMADEO trial implications.
Why the study?
Does telmisartan reduce proteinuria and improve renal and cardiovascular endpoints compared to losartan in hypertensive type 2 diabetic patients with overt nephropathy?
Population
Hypertensive type 2 diabetic patients with overt nephropathy
Comparison
Telmisartan vs Losartan
Design
Review
Loading...
Hypothesis-generating for telmisartan over losartan in diabetic nephropathy; should not yet change practice without quantitative outcome data.
Does telmisartan reduce proteinuria and improve renal and cardiovascular endpoints compared to losartan in hypertensive type 2 diabetic patients with overt nephropathy?
This review discusses the pathophysiology of diabetic kidney disease and the implications of the AMADEO trial comparing telmisartan and losartan for proteinuria reduction.
A 2008 study conducted a review in Hypertensive type 2 diabetes with overt nephropathy. Telmisartan vs. Losartan was evaluated on Renal and cardiovascular endpoints. This review discusses the pathophysiology of diabetic kidney disease and the implications of the AMADEO trial comparing telmisartan versus losartan, though no quantitative results are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: